Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists.

ABSTRACT:

Background

Concerns for hyperkalaemia limit the use of mineralocorticoid receptor antagonists (MRAs). The frequency of MRA-associated hyperkalaemia in real-world settings and the extent of subsequent MRA discontinuation are poorly quantified.

Methods and results

Observational study including all Stockholm citizens initiating MRA therapy during 2007-2010. Hyperkalaemias were identified from all potassium (K⁺ ) measurements in healthcare. MRA treatment lengths and dosages were obtained from complete collection of pharmacy dispensations. We assessed the 1-year incidence and clinical hyperkalaemia predictors, and quantified drug prescription changes after an episode of hyperkalaemia. Overall, 13 726 new users of MRA were included, with median age of 73 years, 53% wome

SUBMITTER: Trevisan M 

PROVIDER: S-EPMC6607478 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature